**Background**

Despite antiretroviral therapy (ART), HIV infection remains associated with higher morbidity/mortality, linked to increased inflammation.

**Objective**

To explore associations between Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) in peripheral blood cells with occurrence of non-AIDS events and mortality during ART.

**Cohort and Sampling**

445 participants (140 cases who experienced non-AIDS events, 305 matched controls, 929 samples total).
- ART naive when enrolled into an ACTG clinical trial.
- Plasma HIV-1 RNA load <400 copies/mL at week 48 after ART initiation and thereafter.

**Cases:** Individuals who died from a non-accidental non-AIDS-related event, or had a myocardial infarction (MI), stroke, non-AIDS-defining malignancy or serious bacterial infection subsequent to week 48 (median of 2.9 years post ART start).

**Controls:** For each case, we identified 2 or 3 controls who had an endpoint-free follow-up time equal or greater than that of the case and were matched by:
- Age (within 10 years; median 45 years).
- Sex (84% male).
- Baseline CD4+ T cell count (within 50 cells/mm³; median 219 cells/mm³).
- ART regimen at week 48 (whether it contained a protease inhibitor or abacavir).
- ACTG parent study.

**Data Generated and Statistical Analysis**

- Levels of CMV and EBV DNA were measured at year 1 in plasma by ELISA.
- Other cellular and soluble biomarkers were obtained from previous projects.
- Conditional logistic regression analysis assessed associations of CMV and EBV DNA with events, adjusted for relevant covariates. Correlation between biomarker levels was assessed with Spearman’s correlations among controls.

**Results**

**Figure 1:** CMV DNA was detected in PBMC in 25% of participants, while EBV DNA was detected in >90%.

**Figure 2:** Higher levels of EBV DNA at all time points were associated with increased risk of events.

**Figure 3:** At year 1, having detectable CMV DNA was associated with increased risk of events.

**Conclusions**

- Clinical trials of anti-viral therapy or vaccines may help to understand how EBV and CMV DNA might influence non-AIDS events.

**Acknowledgments**

This work was supported by the Department of Defense, Pfizer and grants from the National Institutes of Health: AI073167-01A1, AI073221-02A1, AI073172-02A1, AI073209-01A1, AI073248-01A1, AI073228-01A1, AI073189-01A1, AI073190-05A1, AI073234-01A1, AI073192-01A1, AI069601-01A1, AI073193-01A1. This research was conducted, in part, at the AIDS Clinical Trials Group (ACTG) Data and Safety Monitoring Board. The following persons have received support from the National Institutes of Health and other groups: P.W. Hunt, N. Lurain, A. Landay, M. M. Lederman, S. Lada, R.J. Bosch, N. Hoey, M. M. Lederman, A. Vitomirov, J. Chen, D. Smith, C. Moser, A. Vitomirov, A. McKinnon, L. Layman, B. Scott, G. Caballero, S. Lada, R.J. Bosch, M. Hoelig, N. Lurain, A. Landay, M. M. Lederman, P.W. Hunt, D. Smith.

**References**

1. Hoenigl, S. O.P.P. 041007 (2000). Levels of CMV and EBV DNA were correlated with some biomarkers at baseline. Levels of EBV DNA were associated with EBV IgG (r=0.37, p<0.0001), while CMV DNA levels were not associated with CMV IgG (Not shown).
2. Hoenigl, S. 2000. Conditional logistic regression analysis assessed associations of CMV and EBV DNA with events, adjusted for relevant covariates. Correlation between biomarker levels was assessed with Spearman’s correlations among controls.